Foldax continues to have encouraging advancements in multiple trials, gain FDA approval, and large funding. They spoke about the very high potential of this valve in a recent Cleveland Clinic Q&A. Still a ways to go, but the first human patient for the Aortic Valve is apparently doing well. Will continue to monitor the study results. But wow they are now moving to 15 human patients now. Some details below. Will be fun to monitor over the next few years, hopefully the data is positive.
The FDA approves an expanded U.S. clinical study of the Tria biopolymer heart valve. The valve is designed to resist calcification and stresses.
Foldax named cardiovascular Company of the Year by MedTech Outlook.
Foldax® Completes Enrollment in Tria LifePolymer™ Early Feasibility Study - read this article along with other careers information, tips and advice on BioSpace